MENU
FEMY
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

FEMY stock forecast, quote, news & analysis

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas... Show more

FEMY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for FEMY with price predictions
Jul 07, 2026

FEMY's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for FEMY moved out of oversold territory on June 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 77 cases where FEMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 06, 2026. You may want to consider a long position or call options on FEMY as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FEMY just turned positive on June 30, 2026. Looking at past instances where FEMY's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

FEMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FEMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FEMY entered a downward trend on July 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.690) is normal, around the industry mean (4.514). P/E Ratio (0.000) is within average values for comparable stocks, (182.651). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.431). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (4.531) is also within normal values, averaging (76.829).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FEMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FEMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.2B. The market cap for tickers in the group ranges from 126 to 151.33B. ISRG holds the highest valuation in this group at 151.33B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was -10%. LUCY experienced the highest price growth at 59%, while CUPR experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 136%. For the same stocks of the Industry, the average monthly volume growth was 117% and the average quarterly volume growth was 91%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 66
Price Growth Rating: 54
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
FEMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Details
Industry
N/A
Address
3950 Johns Creek Court
Phone
+1 770 500-3910
Employees
54
Web
https://www.femasys.com
FEMY's RSI Oscillator ascending out of oversold territory